Related references
Note: Only part of the references are listed.Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
Jesus San-Miguel et al.
BLOOD (2022)
Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma
Elena Zamagni et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
Neha Korde et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing Feasibility, Challenges, and Direct Comparison with High-Sensitivity Flow Cytometry
Caleb Ho et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2021)
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report
David L. Murray et al.
BLOOD CANCER JOURNAL (2021)
Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches
Juan Jose Lahuerta et al.
BLOOD ADVANCES (2021)
Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?
Ana Jimenez-Ubieto et al.
BLOOD (2021)
Analysis of minimal residual disease in bone marrow by NGF and in peripheral blood by mass spectrometry in newly diagnosed multiple myeloma patients enrolled in the GEM2012MENOS65 clinical trial.
Noemi Puig et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
Stefania Oliva et al.
BLOOD CANCER JOURNAL (2021)
Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry
Angelo Belotti et al.
CANCER MEDICINE (2021)
Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis
Herve Avet-Loiseau et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Bruno Paiva et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982-2017
Oystein O. Langseth et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Measurable residual disease (MRD) assessed by mass spectrometry (MS) in peripheral blood versus next generation sequencing (NGS) in bone marrow in multiple myeloma treated on phase II trial of KRd+ASCT.
Benjamin Avi Derman et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Liquid biopsies for multiple myeloma in a time of precision medicine
Bruna Ferreira et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2020)
Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma
Rafael Alonso et al.
BLOOD ADVANCES (2020)
Measurable residual disease in multiple myeloma: ready for clinical practice?
Leire Burgos et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma
Nikhil C. Munshi et al.
BLOOD ADVANCES (2020)
Prognostic Importance of Measurable Residual Disease (MRD) Kinetics and Progression-Free Survival (PFS) Benefit in MRD plus Patients (Pts) with Ixazomib Vs Placebo As Post-Induction Maintenance Therapy: Results from the Multicenter, Double-Blind, Phase 3 TOURMALINE-MM4 Trial in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Pts
Bruno Paiva et al.
BLOOD (2020)
Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma
Rafael Alonso et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease
Juan-Jose Lahuerta et al.
BLOOD (2019)
Whole Body Diffusion Weighted MRI (WB DWI) for the Management of Multiple Myeloma: High Concordance between MRI Diffuse Pattern and BONE Marrow Plasma CELL Infiltration RATE
Silvia Mangiacavalli et al.
BLOOD (2019)
y Prognostic Value of Diffusion-Weighted Magnetic Resonance Imaging in Newly Diagnosed Multiple Myeloma Patients Treated with up-Front Autologous Transplantation
Elena Fernandez-Poveda et al.
BLOOD (2019)
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis
Manuela Gambella et al.
CANCER (2019)
Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Luciano J. Costa et al.
BLOOD (2019)
Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
L. Rasche et al.
LEUKEMIA (2019)
The impact of response kinetics for multiple myeloma in the era of novel agents
Yuting Yan et al.
BLOOD ADVANCES (2019)
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe)
Cristina Nanni et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma
Leo Rasche et al.
BLOOD (2018)
Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study
Sigrun Thorsteinsdottir et al.
HAEMATOLOGICA (2018)
MRD Testing in Multiple Myeloma: From a Surrogate Marker of Clinical Outcomes to an Every-Day Clinical Tool
Ola Landgren
SEMINARS IN HEMATOLOGY (2018)
Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study
Sigrun Thorsteinsdottir et al.
HAEMATOLOGICA (2018)
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Aurore Perrot et al.
BLOOD (2018)
Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents
Helgi van de Velde et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2017)
Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA
Anna Oberle et al.
HAEMATOLOGICA (2017)
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
Juan-Jose Lahuerta et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study
Philippe Moreau et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy
Jean-Luc Harousseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
J. Flores-Montero et al.
LEUKEMIA (2017)
Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA
Anna Oberle et al.
HAEMATOLOGICA (2017)
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma A Meta-analysis
Nikhil C. Munshi et al.
JAMA ONCOLOGY (2017)
Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis
Jia Li et al.
PLOS ONE (2017)
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
Kenneth C. Anderson et al.
CLINICAL CANCER RESEARCH (2017)
Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma
Leo Rasche et al.
BLOOD (2017)
Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?
C. Pawlyn et al.
LEUKEMIA (2016)
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
Bruno Paiva et al.
BLOOD (2016)
Multiple myeloma: patient outcomes in real-world practice
Kwee Yong et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices
Sundar Jagannath et al.
EXPERT REVIEW OF HEMATOLOGY (2016)
Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality
Joaquin Martinez-Lopez et al.
BLOOD (2015)
Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction
Andy C. Rawstron et al.
BLOOD (2015)
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma
Elena Zamagni et al.
CLINICAL CANCER RESEARCH (2015)
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
Joaquin Martinez-Lopez et al.
BLOOD (2014)
Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myelome
Murielle Roussel et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
N. Puig et al.
LEUKEMIA (2014)
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Lotfi Benboubker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3
Saad Z. Usmani et al.
BLOOD (2013)
Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study
Joaquin Martinez-Lopez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Diagnostic value of whole-body low-dose computed tomography (WBLDCT) in bone lesions detection in patients with multiple myeloma (MM)
Davide Ippolito et al.
EUROPEAN JOURNAL OF RADIOLOGY (2013)
Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma
Jens Hillengass et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Approach to the treatment of multiple myeloma: a clash of philosophies
S. Vincent Rajkumar et al.
BLOOD (2011)
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation
Elena Zamagni et al.
BLOOD (2011)
Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma
Bruno Paiva et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Utility of Flow Cytometry Immunophenotyping in Multiple Myeloma and Other Clonal Plasma Cell-Related Disorders
Bruno Paiva et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2010)
High-dose chemotherapy and autologous bone marrow transplantation for myeloma
T. J. McElwain et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Serum Free Light Chain Ratio, Total κ/λ Ratio, and Immunofixation Results Are Not Prognostic Factors after Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Manuela M. Giarin et al.
CLINICAL CHEMISTRY (2009)
Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials
Jean-Luc Harousseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma
Helgi J. K. van de Velde et al.
HAEMATOLOGICA (2007)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
F Garban et al.
BLOOD (2006)
Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma
GS Nowakowski et al.
BLOOD (2005)
Share Paper
